Zobrazeno 1 - 10
of 62
pro vyhledávání: ''
Autor:
Hans Rabl, Ken Ichi Okada, Matthew H.G. Katz, Bassel F. El-Rayes, Stefan Buettner, Song Cheol Kim, Niek A. Peters, Mary Dillhoff, Christoph Tinchon, Sing Yu Moorcraft, Andrew H. Ko, Eran van Veldhuisen, Khurum Khan, Geertjan van Tienhoven, Bas Groot Koerkamp, Jill Lacy, Alessandro Paniccia, Sunhee S. Kim, Marjolein Y.V. Homs, Philippe Bachellier, Colin J. McKay, Parag J. Parikh, Pietro Addeo, Jessica M. Frakes, Andrea Wang-Gillam, Stephen Clarke, Mustafa Suker, Matthew J. Weiss, Marc G. Besselink, Ammar A. Javed, Quisette P. Janssen, Berend R. Beumer, Peter J. Hosein, Nathan Bahary, Eric A. Mellon, Ian Chau, Casper H.J. van Eijck, Martin D. McCarter, Kyu Pyo Kim, Nigel B. Jamieson, Georgios A. Margonis, Derek Grose, Johanna W. Wilmink, Maria Antonietta Bali, Hiroki Yamaue, Tanios Bekaii-Saab, Jaswinder S. Samra, Brian A. Boone
Publikováno v:
Journal of the National Cancer Institute, 111(8), 782-794. Oxford University Press
Journal of the National Cancer Institute, 111(8):djz073, 782-794. Oxford University Press
J Natl Cancer Inst
Journal of the National Cancer Institute, 111(8):djz073, 782-794. Oxford University Press
J Natl Cancer Inst
Background FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients. The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer (BRPC) remains debated. Methods We performed a systematic re
Autor:
Steven R. Alberts, Eric VanCutsem, Thierry André, Norman Wolmark, Carmen J. Allegra, Rachel Kerr, Thomas J. George, Greg Yothers, Julien Taieb, Axel Grothey, Silvia Marsoni, Qian Shi, Richard M. Goldberg, Charles D. Blanke, Leonard B. Saltz, Aimery de Gramont, Chris Twelves, Daniel G. Haller, Jean Francois Seitz, Anna Dorothea Wagner, Jesse G. Dixon, Michael J. O'Connell, Edoardo Francini
Publikováno v:
J Natl Cancer Inst
Background Adjuvant chemotherapy is a standard treatment option for patients with stage III and high-risk stage II colon cancer. Sex is one of several factors responsible for the wide inter-patient variability in drug responses. Amalgamated data on t
Autor:
Ron D. Hays, Gillian Gresham, Mourad Tighiouart, Greg Yothers, Marcio A. Diniz, Patricia A. Ganz, Sungjin Kim, Michael Luu, Zahra S. Razaee, Andre Rogatko, Steven Piantadosi
Publikováno v:
JNCI Journal of the National Cancer Institute
Background The National Cancer Institute Moonshot research initiative calls for improvements in the analysis and reporting of treatment toxicity to advise key stakeholders on treatment tolerability and inform regulatory and clinical decision making.
Autor:
Francesca Battaglin, Heinz-Josef Lenz
Publikováno v:
JNCI Journal of the National Cancer Institute
Background Constitutional loss of function (LOF) single nucleotide polymorphisms (SNPs) in pattern recognition receptors FPR1, TLR3, and TLR4 have previously been reported to predict oxaliplatin benefit in colorectal cancer. Confirmation of this asso
Autor:
Joseph Vijai, Kenneth Offit, Michael F. Berger, Jonathan W. Lee, Erica S. Kaufmann, Robin Brenner, Yelena Kemel, Angela G. Arnold, Mark E. Robson, Steven D. Leach, Maeve A. Lowery, Vignesh Ravichandran, Gokce Askan, Kenneth H. Yu, Ghassan K. Abou-Alfa, Hannah Maynard, David S. Klimstra, Marinela Capanu, Christina M. Covington, David M. Hyman, Winston Wong, Eileen M. O'Reilly, Christine A. Iacobuzio-Donahue, Peter J. Allen, Semanti Mukherjee, Zsofia K. Stadler, Emmet Jordan, Catherine Tjan, Ahmet Zehir, Erin E. Salo-Mullen, Anna M. Varghese, David P. Kelsen, Diana Mandelker
Publikováno v:
Journal of the National Cancer Institute. 110(10)
BACKGROUND: Identification of pathogenic germline alterations (PGAs) has important clinical and therapeutic implications in pancreas cancer. We performed comprehensive germline testing (GT) in an unselected prospective cohort of patients with exocrin
Autor:
Niki Karachaliou, Santiago Viteri, Sonia Rodríguez, Raimon Puig de la Bellacasa, Ana Drozdowskyj, Patrick C. Ma, Enric Carcereny, Chunping Hu, Antonio Passaro, Isabella Sperduti, Noemi Reguart, Alain Vergnenegre, Jordi Codony Servat, Filipo de Marinis, Peng Cao, Mariacarmela Santarpia, Andrés F. Cardona, Rafael Rosell, Jie Yang, Carles Codony Servat, Mariano Provencio, Charo Garcia Campelo, Sara Pilotto, Jose Miguel Sanchez, Trever G. Bivona, Jia Wei, Guillermo López Vivanco, Christina Teixido, Roger Estrada, X. Li, Alberto Verlicchi, Imane Chaib, Chiara Lazzari, Kirstine Jacobson, Caicun Zhou, Xueting Cai, Migual Angel Molina, Jose Luis Ramirez, Henrik J. Ditzel, Itziar de Aguirre, Cristina Queralt
Publikováno v:
JNCI Journal of the National Cancer Institute
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Chaib, I, Karachaliou, N, Pilotto, S, Codony Servat, J, Cai, X, Li, X, Drozdowskyj, A, Servat, C C, Yang, J, Hu, C, Cardona, A F, Vivanco, G L, Vergnenegre, A, Sanchez, J M, Provencio, M, de Marinis, F, Passaro, A, Carcereny, E, Reguart, N, Campelo, C G, Teixido, C, Sperduti, I, Rodriguez, S, Lazzari, C, Verlicchi, A, de Aguirre, I, Queralt, C, Wei, J, Estrada, R, Puig de la Bellacasa, R, Ramirez, J L, Jacobson, K, Ditzel, H J, Santarpia, M, Viteri, S, Molina, M A, Zhou, C, Cao, P, Ma, P C, Bivona, T G & Rosell, R 2017, ' Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC ', JNCI-Journal of the National Cancer Institute, vol. 109, no. 9, djx014 . https://doi.org/10.1093/jnci/djx014
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Chaib, I, Karachaliou, N, Pilotto, S, Codony Servat, J, Cai, X, Li, X, Drozdowskyj, A, Servat, C C, Yang, J, Hu, C, Cardona, A F, Vivanco, G L, Vergnenegre, A, Sanchez, J M, Provencio, M, de Marinis, F, Passaro, A, Carcereny, E, Reguart, N, Campelo, C G, Teixido, C, Sperduti, I, Rodriguez, S, Lazzari, C, Verlicchi, A, de Aguirre, I, Queralt, C, Wei, J, Estrada, R, Puig de la Bellacasa, R, Ramirez, J L, Jacobson, K, Ditzel, H J, Santarpia, M, Viteri, S, Molina, M A, Zhou, C, Cao, P, Ma, P C, Bivona, T G & Rosell, R 2017, ' Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC ', JNCI-Journal of the National Cancer Institute, vol. 109, no. 9, djx014 . https://doi.org/10.1093/jnci/djx014
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals. We hypothesized that both signal trans
Publikováno v:
Journal of the National Cancer Institute. 109(5)
Background Recent studies have suggested associations between statins and enhanced survival among patients with pancreatic ductal adenocarcinoma (PDAC). However, the relationship between statins, cholesterol, and survival remains unclear. Methods We
Publikováno v:
Journal of the National Cancer Institute. 109(2)
Background Management of resected gallbladder cancer relies on single-arm trials and retrospective observations. Our objective was to evaluate adjuvant therapy in a nationwide data set using causal inference methods to address sources of bias. Method
Autor:
Enrico Mini, Richard M. Goldberg, Julien Taieb, Jean-François Emile, Daniel J. Sargent, Pierre Laurent Puig, Karine Le Malicot, Gunnar Folprecht, Jean-Luc Van Laethem, Steven R. Alberts, Olivier Bouché, Josep Tabernero, Frank A. Sinicrope, Frédérique Penault-Llorca, Qian Shi
Publikováno v:
Journal of the National Cancer Institute. 109(5)
Background: The prognostic value of BRAF and KRAS mutations within microsatellite-unstable (MSI) and microsatellite-stable (MSS) subgroups of resected colon carcinoma patients remains controversial. We examined this question in prospectively collecte
Autor:
Shazia Hassan, Bingshu E. Chen, Michael Crump, Nicole Mittmann, Lois E. Shepherd, C. Tom Kouroukis, Annette E. Hay, Tara Baetz, Vishal Kukreti, Matthew C. Cheung, Kevin Imrie, Nancy A. Risebrough, Jonathan Sussman, David MacDonald, Stephen Couban, Yuyao Song, Pierre Desjardins, Ralph M. Meyer, David Szwajcer, Al Le
Publikováno v:
Journal of the National Cancer Institute. 107(7)
BACKGROUND The NCIC CTG LY.12 study showed that gemcitabine, dexamethasone, and cisplatin (GDP) were noninferior to dexamethasone, cytarabine, and cisplatin (DHAP) in patients with relapsed or refractory aggressive histology lymphoma prior to autolog